John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.
Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.
Health Secur. 2020 May/Jun;18(3):241-249. doi: 10.1089/hs.2020.0043. Epub 2020 Apr 29.
The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.
COVID-19 大流行清楚地提醒人们，具有流行和大流行潜力的新发传染病（EIDs）可能造成严重后果。疫苗的开发、扩大规模和商业化是一个漫长、昂贵且风险高的企业，需要大量的前期规划，并且不能保证成功。新发传染病是全球卫生准备工作的一个特别具有挑战性的目标，包括疫苗开发。对于支持和维持疫苗行业参与新发传染病疫苗开发的挑战、经验教训和潜在解决方案，关注不够。从最近刚果民主共和国的埃博拉疫情以及 2009 年 H1N1 流感、2014-2016 年埃博拉和 2015-2016 年寨卡疫情中吸取教训，我们提供了对新发传染病疫苗开发所面临挑战的看法，并建议在近期内优先考虑其他解决方案。这 6 项建议侧重于缩短疫苗开发时间表和增加业务确定性，以降低公司的风险。全球卫生安全界有机会利用当前的势头，为新发传染病疫苗设计一个可持续的模式。
